Publication | Open Access
108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
12
Citations
0
References
2022
Year
Radiation MedicineOncologyRadiation TherapyCancer ManagementEfficacy OutcomesPharmacotherapyCancer TreatmentMedicineRadiation OncologyLung CancerStage IiiSequential Chemoradiotherapy
No additional data available for this publication yet. Check back later!